Zastaprazan（Cat No.:I038662）is a novel potassium-competitive acid blocker (P-CAB) that inhibits the H⁺/K⁺-ATPase enzyme in gastric parietal cells, effectively reducing stomach acid secretion. Unlike traditional proton pump inhibitors (PPIs), Zastaprazan acts rapidly and reversibly, offering quicker symptom relief and prolonged acid suppression. It is being explored for treating gastroesophageal reflux disease (GERD), peptic ulcers, and related acid-related disorders. With improved stability and a favorable pharmacokinetic profile, Zastaprazan provides consistent therapeutic efficacy and better control of nocturnal acid breakthrough, representing a next-generation alternative to conventional acid-suppressive therapies.